 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C15H21NO2 |
| Molar mass | 247.338 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
threo-4-Methylmethylphenidate (4-MeTMP) is astimulant drug related tomethylphenidate. It is slightly less potent than methylphenidate and has relatively low efficacy at blockingdopaminereuptake despite its highbinding affinity, which led to its investigation as a possible substitute drug for treatment of stimulant abuse.[1] On the other hand, several other simple ring-substituted derivatives ofthreo-methylphenidate such as the 4-fluoro and 3-chloro compounds are more potent than methylphenidate both in efficacy asdopamine reuptake inhibitors and in animal drug discrimination assays.[2][3][4]
4-Methylmethylphenidate was banned in the UK as aTemporary Class Drug from June 2015 following its unapproved sale as adesigner drug.[5][6][7]
In the United States, 4-methylmethylphenidate may be considered illegal if intended for human consumption under thefederal analogue act as a structural analog of methylphenidate.
In the United States, on September 22, 2023, the DEA filed a proposed rule for placement ofethylphenidate into Schedule I status, which would include its isomers. 4-Methylmethylphenidate is a positional isomer of ethylphenidate and thus the scheduling of ethylphenidate into Schedule I status would cause 4-methylmethylphenidate to be a Schedule I substance as well.[8]
